STOCK TITAN

Invizyne Technologies (IZTC) 10-Q Filings

IZTC NASDAQ

Ticker history: IZTC became EXOZ (eXoZymes Inc.) on .

Here are the 10-Q quarterly reports from Invizyne Technologies Inc. (IZTC) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-Q covers the quarterly report filed between annual reports, so if you follow IZTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IZTC filings page.

Rhea-AI Summary

eXoZymes Inc. reported no revenue for the quarter and a six-month net loss of $4,216,707, or $0.50 per share, driven by increased R&D and G&A spending. Cash and cash equivalents totaled $6,985,858 at June 30, 2025, down from $9.72 million at year-end 2024, and working capital was approximately $6,314,087. The company offset research costs with government grants but grant receivables fell to $257,407.

The company raised net IPO proceeds of $15,206,543 in November 2024 and used funds for operations and debt repayment. Management disclosed substantial doubt about going concern and identified a material weakness in internal controls. Subsequent events include a July 1, 2025 NSF-related industrial partnership award (company share $3.0M) and board approval of an expanded 2025 equity incentive plan.